Epidiferphane (University of Florida)

Epidiferphane is a multi-ingredient nutritional supplement developed by the University of Florida to mitigate chemotherapy-induced toxicities in patients with breast cancer. It is specifically designed to reduce taxane-induced peripheral neuropathy and anemia, common side effects of agents like paclitaxel and docetaxel that often lead to dose reductions or treatment discontinuation. The supplement is a combination of bioactive plant extracts, likely including turmeric, broccoli, and green tea. Pre-clinical studies in mouse models have demonstrated its efficacy in reducing both neuropathy and anemia. Epidiferphane is currently being evaluated in a Phase 1/2 clinical trial (NCT05074290) to determine its safety, maximum tolerated dose, and pharmacokinetics when administered alongside standard taxane chemotherapy regimens. By attenuating these toxicities, the supplement aims to maintain the relative dose intensity of chemotherapy, potentially improving clinical outcomes such as progression-free and overall survival.

Brand names

Epidiferphane